Although COVID-19 begins as a respiratory pneumonia, we are now discovering it causes
an intense inflammatory response accompanied by systemic microangiopathy. In reflecting …

Background Recent data suggests an association between blood hyperviscosity and both
propensity for thrombosis and disease severity in patients with COVID‐19. This raises the …

To reveal if coagulopathies relate to the course of COVID-19, we examined 255 patients with
moderate and severe COVID-19, receiving anticoagulants and immunosuppressive drugs …

In late December 2019 an outbreak of a novel coronavirus (SARS-CoV-2) causing severe
pneumonia (COVID-19) was reported in Wuhan, Hubei Province, China. A common finding …

Coagulation abnormalities were common findings in critically ill patients affected by
coronavirus infection disease (COVID)-19 and often correlated to more severe illness and …

Patients with coronavirus disease 2019 (COVID-19) frequently experience a coagulopathy
associated with a high incidence of thrombotic events leading to poor outcomes. Here …

Abstract The 2019 coronavirus disease (COVID-19) presents with a large variety of clinical
manifestations ranging from asymptomatic carrier state to severe respiratory distress …

The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number …

Critically ill patients with COVID-19 pneumonia suffered both high thrombotic and bleeding
risk. The effect of SARS-CoV-2 on coagulation and fibrinolysis is not well known. We …

COVID‐19 is a global pandemic with a daily increasing number of affected individuals.
Thrombosis is a severe complication of COVID‐19 that leads to a worse clinical course with …